5-(3,5-二氯苯基)-1H-四唑 | 92712-49-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(3,5-二氯苯基)-1H-四唑
• 英文名称: 5-(3,5-dichlorophenyl)-1H-tetrazole
• 英文别名: 5-(3,5-dichlorophenyl)-2H-tetrazole
• CAS: 92712-49-7
• 化学式: C₇H₄Cl₂N₄
• 分子量: 215.042
• InChiKey: VCYMSAGOTYBIHM-UHFFFAOYSA-N

物化性质

• 熔点：
  205-208°C
• 沸点：
  410.2±55.0 °C(Predicted)
• 密度：
  1.574±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  按规定使用和贮存的情况下，该物质不会分解，并应避免接触氧化物、热量、光线及明火。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38

反应信息

• 作为反应物：
  描述：

  5-(3,5-二氯苯基)-1H-四唑 在 三乙胺 、 morpholine-iodine complex 作用下， 以 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 19.0h， 生成 5-(3,5-Dichlorophenyl)-2-(3-iodoprop-2-ynyl)tetrazole
  参考文献：
  名称：

  Synthesis and quantitative structure-activity relationship analysis of N-triiodoallyl- and N-iodopropargylazoles. New antifungal agents

  摘要：

  New series of N-(2,3,3-triiodoallyl) and N-(3-iodopropargyl) azole derivatives (100 compounds) involving pyrrole, pyrazole, imidazole, triazole, and tetrazole nuclei were synthesized successively with the aid of quantitative structure-activity relationship (QSAR) analysis to obtain potent antifungal agents. Starting from the derivatives of nitropyrrole-containing antibiotics, the QSAR analysis of the pyrrole derivatives against Candida albicans and Trichophyton mentagrophytes strains indicated the positive contribution of the nitro group and negative effect of the size of molecule. Further application of the QSAR analysis on the multi-azole derivatives revealed the importance of hydrophobicity and electronegativity as well as steric effect to the activities and led to the synthesis of one of the most potent iodo compounds, 2-(2,3,3-triiodoallyl)tetrazole (67, ME1401).

  DOI：

  10.1021/jm00386a019
• 作为产物：
  描述：

  3,5-二氯苯腈 在 sodium azide 、 氯化铵 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 5-(3,5-二氯苯基)-1H-四唑
  参考文献：
  名称：

  Synthesis and quantitative structure-activity relationship analysis of N-triiodoallyl- and N-iodopropargylazoles. New antifungal agents

  摘要：

  New series of N-(2,3,3-triiodoallyl) and N-(3-iodopropargyl) azole derivatives (100 compounds) involving pyrrole, pyrazole, imidazole, triazole, and tetrazole nuclei were synthesized successively with the aid of quantitative structure-activity relationship (QSAR) analysis to obtain potent antifungal agents. Starting from the derivatives of nitropyrrole-containing antibiotics, the QSAR analysis of the pyrrole derivatives against Candida albicans and Trichophyton mentagrophytes strains indicated the positive contribution of the nitro group and negative effect of the size of molecule. Further application of the QSAR analysis on the multi-azole derivatives revealed the importance of hydrophobicity and electronegativity as well as steric effect to the activities and led to the synthesis of one of the most potent iodo compounds, 2-(2,3,3-triiodoallyl)tetrazole (67, ME1401).

  DOI：

  10.1021/jm00386a019

文献信息

• Macrocyclic hepatitis C serine protease inhibitors
  申请人：Miao Zhenwei

  公开号：US20050153877A1

  公开（公告）日：2005-07-14

  The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I、II或III的化合物，或其药用可接受的盐、酯或前药： 其中W是取代或未取代的杂环环系。这些化合物抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给患有HCV感染的对象进行给药。本发明还涉及通过给主体投药包含本发明化合物的药物组合物来治疗主体HCV感染的方法。
• [EN] AZETIDINES AS EP2 ANTAGONISTS<br/>[FR] AZÉTIDINES
  申请人：PFIZER LTD

  公开号：WO2009063365A1

  公开（公告）日：2009-05-22

  The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids (leiomyomata)and to intermediates usefulin their synthesis and to compositions containing them.

  本发明涉及EP2拮抗剂的一类通用式(I)的氮杂环丁烷化合物，其中变量和取代基如本文所定义，特别是EP2拮抗剂化合物，以及它们在医学上的应用，特别是在治疗子宫内膜异位症和/或子宫肌瘤（平滑肌瘤）方面，以及在其合成中有用的中间体和含有它们的组合物。
• VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF
  申请人：Wakil Adil Salih

  公开号：US20220081381A1

  公开（公告）日：2022-03-17

  Provided are vitamin D 3 derivatives of formula (I), pharmaceutical compositions thereof, and pharmaceutical or medical uses thereof for treating metabolic disease, a liver disease, obesity, diabetes, cardiovascular disease, or cancer in a patient in need thereof.

  提供了公式（I）的维生素D3衍生物，以及其制成的药物组合物，以及用于治疗代谢性疾病、肝脏疾病、肥胖症、糖尿病、心血管疾病或癌症的药物或医疗用途，用于需要治疗的患者。
• MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Miao Zhenwei

  公开号：US20090304629A1

  公开（公告）日：2009-12-10

  The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及I、II或III式化合物，或其药学上可接受的盐、酯或前药： 其中W是取代或未取代的杂环环系。这些化合物能够抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包括上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给予包括本发明的化合物的制药组合物来治疗受试者的HCV感染的方法。
• Azetidines As EP2 Antagonists
  申请人：Skerratt Sarah Elizabeth

  公开号：US20100256109A1

  公开（公告）日：2010-10-07

  The present invention relates to a class of EP2 antagonistazetidines of general formula (I), wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids (leiomyomata) and to intermediates usefulin their synthesis and to compositions containing them.

  本发明涉及一类EP2拮抗剂氮杂环丙烷，其通式为（I），其中变量和取代基的定义如本文所述，特别是EP2拮抗剂化合物，它们在医学上的用途，特别是在治疗子宫内膜异位症和/或子宫肌瘤（平滑肌瘤）方面的用途，以及在其合成过程中有用的中间体和含有它们的组合物。